New & Improved Formula Builds on Trusted 30-Year
Heritage of Meeting Consumers' Lens Care Solution
Needs
LAVAL, Quebec, May 22, 2017 /CNW/ -- Valeant Pharmaceuticals
International, Inc.'s (NYSE: VRX and TSX: VRX) wholly owned
subsidiary, Bausch + Lomb, a leading global eye health company,
today announced the launch of renu® Advanced Formula
multi-purpose solution for soft and silicone hydrogel contact
lenses. This unique formula combines three disinfectants and two
moisture agents to provide excellent lens cleaning and
disinfection, in addition to all-day comfort.
"At Valeant, we are keenly focused on continuing to drive
innovation and enhance our existing portfolio using the most
current scientific and clinical research to better meet the needs
of our customers and their patients," said Joseph C. Papa, Chairman and CEO of Valeant.
"The Bausch + Lomb Consumer Healthcare business remains a critical
driver for our global eye health business, offering a wide range of
over-the-counter supplements, eye care, and lens care
products."
Bausch + Lomb was the first company to bring an 'all-in-one'
multi-purpose disinfection solution to market with the launch of
the renu brand in 1987. Today, the brand has grown to more than
three million users. The new and improved renu Advanced Formula
solution will replace renu sensitive and renu fresh solutions
beginning in June in major retailers.
Bausch + Lomb's Consumer Healthcare business is one of the
fastest growing consumer healthcare businesses in the
U.S.1 and the No. 1 category growth contributor (62%) in
the eye care category.2 The product portfolio
includes such well-known brands as Biotrue®
multi-purpose solution the No. 1 multi-purpose solution brand in
households with the highest loyalty metrics3, and
PreserVision® AREDS 2 Formula Eye Vitamin and Mineral
Supplement (120 ct.), the No. 1
selling SKU in the vitamin category and the largest contributor to
vitamin category growth.4
In addition to its product portfolio, Bausch + Lomb's Consumer
Healthcare business has a rich R&D pipeline that relies on a
research strategy to develop new formulations for new and existing
products and line extensions, among others. This includes the
company's new redness reliever candidate, brimonidine tartrate
ophthalmic solution, 0.025% (Luminesse™5), which is
currently under review by the U.S. Food and Drug
Administration.
About Valeant
Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a
multinational specialty pharmaceutical company that develops,
manufactures and markets a broad range of pharmaceutical products
primarily in the areas of dermatology, gastrointestinal disorders,
eye health, neurology and branded generics. More information about
Valeant can be found at www.valeant.com.
About Bausch + Lomb
Bausch + Lomb, a Valeant Pharmaceuticals International, Inc.
company, is a leading global eye health organization that is solely
focused on protecting, enhancing and restoring people's eyesight.
Its core businesses include over-the-counter supplements, eye care
products, ophthalmic pharmaceuticals, contact lenses, lens care
products, ophthalmic surgical devices and instruments. Bausch +
Lomb develops, manufactures and markets one of the most
comprehensive product portfolios in our industry, which is
available in more than 100 countries.
Forward-looking Statements
This press release may contain forward-looking statements which
may generally be identified by the use of the words "anticipates",
"if approved", "expects," "intends," "plans," "should," "could,"
"would," "may," "will," "believes," "estimates," "potential,"
"target," or "continue" and variations or similar expressions.
These statements are based upon the current expectations and
beliefs of management and are subject to certain risks and
uncertainties that could cause actual results to differ materially
from those described in the forward-looking statements. These risks
and uncertainties include, but are not limited to, risks and
uncertainties discussed in the Company's most recent annual or
quarterly report and detailed from time to time in Valeant's other
filings with the Securities and Exchange Commission and the
Canadian Securities Administrators, which factors are incorporated
herein by reference. Readers are cautioned not to place undue
reliance on any of these forward-looking statements. These
forward-looking statements speak only as of the date hereof.
Valeant undertakes no obligation to update any of these
forward-looking statements to reflect events or circumstances after
the date of this press release or to reflect actual outcomes,
unless required by law.
1 Based on retail sales
2 Based on IRI Data: Eye Care Category Includes
General Eye Care, Lens Care, Vision Accessories, & Eye
Vitamins
3 IRI data. Latest 52 wks. ending
01/01/17
4 IRI
data. Latest 52 wks. ending 01/01/17
5 Provisionally
approved name.
Contact Information:
Elif McDonald
514-856-3855
877-281-6642 (toll
free)
elif.mcdonald@valeant.com
Media:
Lainie Keller
908-927-0617
lainie.keller@valeant.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/bausch--lomb-introduces-renu-advanced-formula-multi-purpose-solution-300461256.html
SOURCE Valeant Pharmaceuticals International, Inc.